Intraportal donor bone marrow transplantation improves intestinal allograft survival in rats under FK506-based immunosuppression

D. S. Sun, T. Yagi, T. Oyama, H. Matsukawa, H. Matsuda, H. Sadamori, M. Inagaki, J. Matsuoka, H. Iwagaki, N. Tanaka

Research output: Contribution to journalArticle

4 Citations (Scopus)


Donor-specific immunosuppression is important in transplant surgery. We examined the effect of intraportal donor-specific bone marrow transplantation on heterotopic small bowel transplantation in the high responder rat combination, ACI to Lewis. The study comprised five treatment groups: untreated controls (group 1); FK506 alone (group 2); low-dose predonine + FK506 (group 3); high-dose predonine + FK506 (group 4); and intraportal donor-specific bone marrow transplantation + FK506 (group 5). Intraportal transplantation was performed pre-operatively and FK506 and predonine given postoperatively. Intestinal allograft survival and changes of intragraft cytokine expression were analysed using the reverse transcription polymerase chain reaction. Allograft survival (mean ± SD) was lowest in group 1 and greatest in group 5. The group 5 treatment regimen also down-regulated interferon-γ and interleukin-2 transcription in the transplanted intestine. Intraportal donor bone marrow transplant combined with FK506 immunosuppression was found therefore to be the most beneficial treatment regimen.

Original languageEnglish
Pages (from-to)281-289
Number of pages9
JournalJournal of International Medical Research
Issue number4
Publication statusPublished - Jan 1 2003



  • Bone marrow transplantation
  • FK506
  • Interferon (IFN)-γ
  • Interleukin (IL)-2
  • Small bowel transplantation
  • Steroids

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Biochemistry, medical

Cite this